This acquisition significantly strengthens Stereotaxis' position as a leading platform for the full spectrum of endovascular procedures, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for electrophysiology, interventional cardiology and neurointerventions.

Robocath, headquartered in Rouen, France, has developed the most advanced mechanical robotic technology for interventional cardiology and neurointerventions. Its flagship R-One+ system is the only commercially available robotic solution currently available for percutaneous coronary interventions in Europe, with fifteen commercial R-One+ systems installed globally. Robocath is developing a next-generation system, designed to enable simultaneous manipulation of up to five interventional devices. Initial first-in-human procedures were recently successfully completed in France. Robocath's differentiated technologies are supported by a robust intellectual property portfolio.

The combination of Stereotaxis' magnetic navigation technology and Robocath's mechanical robotic system creates a highly differentiated fully-robotic solution for endovascular surgery. Stereotaxis uses precise computer-controlled magnetic fields to enable unprecedented navigation of the distal tip of interventional devices, while Robocath's platform provides multi-device control at the bedside. There is defined value to each technology on a standalone basis. Together, these technologies offer a powerful and synergistic approach to improving procedural precision, efficiency, and outcomes.